TACSTD2 and cancer: TROP2 loss by promoter methylation has already been reported for different cancer types, such as tamoxifen-resistant breast cancer18, lung adenocarcinoma19, cholangiocarcinoma20, renal cell cancer21 and hepatocellular carcinoma22.